Abstract The role of cyclic ADP-ribose (cADPR) as a second messenger and modulator of the mTOR pathway downstream of dopamine (DA) receptors and/or CD38 was re-examined in the mouse. ADP-ribosyl activity was low in the membranes of neonates, but DA stimulated it via both D1-and D2-like receptors. ADP-ribosyl cyclase activity increased significantly during development in association with increased expression of CD38. The cADPR binding proteins, FKBP12 and FKBP12.6, were expressed in the adult mouse striatum. The ratio of phosphorylated to nonphosphorylated S6 kinase (S6K) in whole mouse striatum homogenates decreased after incubation of adult mouse striatum with extracellular cADPR for 5 min. This effect of cADPR was much weaker in MPTP-treated Parkinson's disease model mice. The inhibitory effects of cADPR and rapamycin were identical. These data suggest that cADPR is an endogenous inhibitor of the mTOR signaling pathway downstream of DA receptors in the mouse striatum and that cADPR plays a certain role in the brain in psychiatric and neurodegenerative diseases.
Introduction
Dr. Toshiharu Nagatsu and the first author (H.H.) examined monoamine oxidase A and B (Nagatsu et al. 1981; Nakano et al. 1985 and ) and serotonin (Suzuki et al. 1983; Furuya et al. 1985) in rodent neuroblastoma clones, with permission from Dr. Nirenberg, National Institutes of Health, USA. Dr. Nagatsu suggested that Higashida focused on amines and Parkinson's disease. However, Higashida's and his fellow researchers' main interests at that time were on bradykinin, muscarinic acetylcholine receptors and their coupling to phospholipase C (Yano et al. 1984; Higashida and Brown 1986; Fukuda et al. 1988 ) and later to ADP-ribosyl cyclase (Higashida et al. 2001a; Jin et al. 2007 ). Higashida et al. concentrated on intracellular signaling leading to the modulation of membrane excitation and acetylcholine release . However, when Higashida et al. used neuroblastoma cells as a tool to overexpress dopamine (DA) receptors (Higashida et al. 2013) , they realized that there is little information on the coupling of DA receptors and ADPribosyl cyclase to a potential second messenger, cyclic ADP-ribose (cADPR), which is downstream of DA receptors.
DA receptors are involved in many physiological functions, such as extrapyramidal motor control, short-term memory, attention, and reward (Greengard 2001; Iversen and Iversen 2007; Nagatsu 2007; Nagatsu and Nagatsu 2016) . In contrast, abnormal activity of the DA system has been implicated in neurological and psychiatric disorders, such as Parkinson's disease (PD), schizophrenia, bipolar disorder, and attention deficit hyperactivity disorder (Nagatsu 2007) . Therefore, the study of DA receptor-mediated intracellular signal transduction has been a primary approach for understanding the physiological functions or PD-related aspects of DA-related cellular responses (Barker et al. 2015) .
From the viewpoint of signal transduction, D1-and D2-class DA receptor subtypes positively and negatively regulate adenylyl cyclase, respectively (Greengard 2001; Missale et al. 1998; Seeman and Van Tol 1994; Volkow and Morales 2015) . Stimulation of D2 receptors can increase intracellular Ca 2? concentrations by mobilizing Ca 2? from inositol-1,4,5-trisphosphate-sensitive stores (Frégeau et al. 2013) . Increases in intracellular free calcium concentration ([Ca 2? ] i ) seem to be mediated by the interaction of DA receptors with neuronal calcium sensor-1 or calcyon (Bergson et al. 2003) . However, we recently reported a new pathway that is dependent on cyclic ADPribose (cADPR) (Lee 2012) downstream of DA receptors and CD38 with ADP-ribosyl cyclase activity in rodents (Higashida et al. 2013) .
cADPR is a co-factor of Ca 2? -induced Ca 2? release that activates Ca 2? release from ryanodine receptors in microsomes (Lee 2012; Hua et al. 1994; Okamoto et al. 2014; Higashida et al. 2001b) . cADPR is synthesized from b-NAD ? by both cytosolic and membrane-bound forms of ADP-ribosyl cyclase and/or CD38 (Ceni et al. 2003; De Flora et al. 2004; Higashida et al. 1999 and 2007; Kim, 2014; Salmina et al. 2010) . ADP-ribosyl cyclase activity increases upon stimulation of various receptors; some of this activity is observed in only neonates, not adult tissues of the same organs Zhang et al. 2005) .
The mammalian target of rapamycin (mTOR) pathway has emerged as a regulator of neuroplasticity in the central nervous system (CNS; Bockaert and Marin 2015; Tramutola et al. 2016) . mTOR is a Ser/Thr protein kinase complex that responds to multiple extracellular stimuli, such as nutrients, energy, growth factors, and mitogens that regulate cell growth, cell survival, transcription, and protein synthesis (Wullschleger et al. 2006; Hoeffer and Klann 2010; Sukhbaatar et al. 2016) . Deregulation of the mTOR pathways occurs in pathological conditions, such as cancer and neurodegenerative diseases characterized by long-term alterations in protein expression (Wullschleger et al. 2006 ). Administration of L-DOPA in a mouse model of Parkinson's disease leads to DA D1 receptor-mediated activation of mTOR complex 1 (mTORC1), which has been implicated in several forms of synaptic plasticity (Hoeffer and Klann 2010) . This response occurs selectively in GABAergic medium spiny neurons that project directly from the striatum to the output structures of the basal ganglia. The L-DOPA-mediated activation of mTORC1 persists in mice that develop dyskinesia (Santini et al. 2009 ). Moreover, the mTORC1 inhibitor rapamycin prevents the development of dyskinesia without affecting the therapeutic efficacy of L-DOPA. Thus, the mTORC1 signaling cascade represents a promising target for therapeutics to treat the negative motor symptoms induced by antiparkinsonian therapies (Santini et al. 2009; Lipton and Sahin 2014; Buszczak et al. 2014; Roohi and Hojjat-Farsangi 2016) . mTORC1 is sensitive to rapamycin via competition between a mTOR regulatory protein (Raptor) and FKBP12-rapamycin for binding to the FRB domain (Buszczak et al. 2014; Thomson et al. 2009; Hoeffer et al. 2008; Hausch 2015) . mTOR signaling is suppressed by rapamycin and FK506 in the brain. Removal of neuronal FKBP resulted in enhanced mTORC1 formation and increased phosphorylation of S6 kinase 1 (S6K1; Thomson et al. 2009 ). Thus, FKBP12 appears to repress mTORC1 activity. Another member of the FKBP family, FKBP12.6, can mediate the immunosuppressive effects of FK506 and act as a receptor for cADPR (Hoeffer et al. 2008; Hausch 2015; Noguchi et al. 1997; Zhang et al. 2009 ). The roles of FK12.6 and the FKBP12.6-cADPR complex were in part demonstrated by immunoblotting analysis of the striatum of control and MPTP-treated mice (Higashida et al. 2013) . Here, we reexamined the mouse striatum to support our hypothesis that cADPR functions as an endogenous modulator of the mTOR pathway downstream of DA receptors.
Materials and methods

Membrane preparation
Crude membrane fractions were prepared as described previously from male ICR mice for the ADP-ribosyl cyclase assays (Higashida et al. 1997) .
Fluorometric measurement of ADP-ribosyl cyclase
ADP-ribosyl cyclase activity was determined fluorometrically using a technique based on measuring the conversion of b-NGD ? into the fluorescent product cyclic GDP-ribose (cGDPribose), as described previously (Higashida et al. 1997; Higashida et al. 2002; Graeff and Lee 2002) . The samples were then excited at 300 nm, and fluorescence emission was monitored continuously at 410 nm with a spectrofluorophotometer (RF-6000; Shimadzu, Kyoto, Japan).
Incubation of the striatum
Striata were isolated from the brains of 9-week-old male ICR mice or mice treated with an intraperitoneal injection of MPTP (20 mg/kg, 4 times/day at 2-h intervals; Higashida et al. 2013) . The striata were kept in medium (pH 7.3) containing 124 mM NaCl, 5 mM KCl, 1.24 mM KH 2 PO 4 , 2 mM CaCl 2 , 25.9 mM NaHCO 3 , and 10 mM glucose for 1 h at room temperature and bubbled with a mixture of 95% O 2 /5% CO 2 . The tissue was further incubated with or without 100 lM cADPR, 100 nM DA or 100 nM DA ? 100 lM cADPR for 5 min at 32°C. Certain tissues were preincubated with 8-Bromo-cADPR (Sigma-Aldrich Sweden AB, Stockholm, Sweden) for 1 h. Then, tissues were immediately homogenized in lysis buffer containing 0.1% Triton X-100, 10% glycerol, 1.5 mM EDTA, 0.5 mM Na 3 VO 4 , 10 mM NaF, and 19 protease inhibitor cocktail (Roche, Mannheim, Germany). Protein concentration was determined by BCA assay (Thermo Fisher Scientific, Inc., Waltham, MA).
Western blotting and PCR
Aliquots of 30 lg of protein were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The membranes were incubated with anti-phospho-p70 S6 K (Thr389) and anti-p70 S6 K antibodies (both from Cell Signaling Technology, Beverly, MA) in blocking buffer overnight at 4°C and then for 3 h at room temperature (both antibodies were diluted 1:500). The membranes were then processed and visualized as described previously (Higashida et al. 2013) . RT-PCR analysis was performed as described previously (Higashida et al. 2013) .
Statistics
All results are expressed as the mean ± SEM. One-or twotailed Student's t tests and one-way ANOVA combined with the Bonferroni test were used to analyze data with unequal variance between groups. Two-way ANOVA was used to assess Treatment 9 Concentration interaction. In all analyses, P \ 0.05 was considered to indicate statistical significance.
Results ADP-ribosyl cyclase activity in the mouse striatum ADP-ribosyl cyclase activity was measured in crude membrane fractions isolated from the striatum of mice at various ages. Basal ADP-ribosyl cyclase activity was very low, i.e., approximately 0.1-1.6 pmol cGDPR formed/min/ mg protein in preparations from 1-3 day prenatal and 1-5 day postnatal mice, respectively. ADP-ribosyl cyclase activity increased sharply with age after postnatal day 5 ( Fig. 1 ; P \ 0.001, F (12,65) = 59.68, R 2 = 0.9168, oneway ANOVA), reaching a very high level by 12 days of age (21.6 ± 3.7 pmol cGDPR formed/min/mg protein, n = 12), which was 40-fold higher than the basal activity at birth (P \ 0.001, Bonferroni's post hoc test).
Sensitivity to dopamine
ADP-ribosyl cyclase activity was analyzed in striatal membranes from mouse neonates at birth (day 0) and postnatal days 1-11 in the presence of 100 nM DA in the reaction mixture. From neonatal day 1 to 4, the increase ranged from 130 to 310%. However, after 12 days, DA-induced activation dropped to less than 105 ± 10% and remained at this level until the adult stage.
The concentration-response relationship to DA was examined (Fig. 2) . The increases induced by DA (with or without 10 nM GTP), SKF38393 (SKF, a D1-like agonist), and bromocriptine mesylate (BC, a D2-like agonist) were dose-dependent. Two-way ANOVA demonstrated significant Treatment (±GTP) 9 Concentration (DA) interaction (P = 0.0261, F (6,126) = 2,49; Fig. 2a) . One-way ANOVA demonstrated significant difference in experiments with SKF (P \ 0.001, F (5,54) = 12.88, R 2 = 0.5439) and BC treatment (P \ 0.001, F (4,45) = 17.00, R 2 = 0.6018; Fig. 2b ). The maximum effects of these three agents were obtained at different concentrations between 1 and 100 nM. The maximum response of 202.8 ± 21.4% of the control (n = 10, P \ 0.01, Bonferroni's post hoc test) was obtained with 100 nM DA. Significant increases to 183.0 ± 12.2% (n = 10, P \ 0.01, Bonferroni's post hoc test) and 157.9 ± 5.3% (n = 10, P \ 0.01) of the control were obtained with 10 nM SKF and 1 nM BC, respectively.
CD38 expression
We examined whether the increased ADP-ribosyl cyclase activity is due to an increase in CD38 expression. While a band of approximately 42 kDa was detected in the 1-week striatum, CD38 protein abundance was significantly increased after 2 weeks and in adult mice (10 weeks old), as shown by Western blotting (Fig. 3) . RT-qPCR analysis indicated that CD38 mRNA expression levels increased significantly with age (data not shown). CD38 mRNA expression relative to b-actin expression was approximately 29.8-fold higher in adult mice (2 weeks old) than in mice at postnatal day 1 (P \ 0.001, two-tailed t test).
Expression of FKBP in the mouse brain
Next, the expression of FKBP12 and the close homolog FKBP12.6 was examined in various brain regions of 9-week-old male mice by RT-PCR. FKBP12 was ubiquitously detected in four regions (cerebrum, cerebellum, hypothalamus and striatum) and the pituitary, with no significant differences among them, based on the relative expression normalized to b-actin (Higashida et al. 2013) . In contrast, the FKBP12.6 expression level was lower in the striatum than in the cerebrum, cerebellum, and hypothalamus in 9-week-old male mice (Fig. 4) , suggesting regionspecific expression. The result provides minimal necessary evidence for a functional role of cADPR/FKBP12 or cADPR/FKBP12.6 binding complexes in mTOR signaling in the striatum.
Effects of cADPR on S6 kinase
The mammalian target of rapamycin (mTOR) activates S6 kinase (S6 K), which is responsible for phosphorylation of the ribosomal protein S6 (S6), a component of the 40S ribosomal subunit (Bockaert and Marin 2015; Buszczak et al. 2014) . cADPR (100 lM) was added to the incubation Quantitative data are shown as the mean ± SEM (n = 5 independent experiments) of FKBP12.6/actin. One-way ANOVA followed by Bonferroni's post hoc test: F 4,12 = 30.99, *P \ 0.002, **P \ 0.001. Modified from Fig. 6 of our previous report [9] medium for 9-week-old mouse striatum samples for 5 min with or without DA receptor stimulation by 100 nM DA (Fig. 5a, b) . DA itself did not cause significant inhibition of S6 K phosphorylation, being calculated as the percentage change between 0 and 5 min (P-S6 K/S6 K at 5 min divided by P-S6 K/S6 K at 0 min): 1.28 ± 0.16 (n = 22; Table 1 ) in the absence and 1.42 ± 0.25 (n = 5) in the presence of DA. This result well accord with the report in the nucleus accumbens by D1 stimulation (Sutton and Caron 2015) . One-way ANOVA demonstrated no significant difference between treatments without ( Fig. 5a ; P [ 0.05, F (2,43) = 2.595, R 2 = 0.1077) or with DA receptor stimulation ( Fig. 5b ; P = 0.2741, F (2,45) = 1.332, R 2 = 0.0558). In whole-cell homogenates, S6 K phosphorylation at Thr389 significantly decreased in both the presence and absence of DA (n = 16 mice each, P \ 0.01, Bonferroni's post hoc test). This cADPR-induced decrease in S6 K phosphorylation was reversed by prior administration of 100 lM 8-bromo-cADPR, a cADPR antagonist (n = 14, P \ 0.02, Bonferroni's post hoc test). The total amount of S6 K was unaffected by cADPR treatment with or without DA or 8-bromo-cADPR.
The effects of cADPR were compared with those of rapamycin. Rapamycin was added to the incubation medium 1 h prior to experiments at a final concentration of 100 lM (Table 1) . One-way ANOVA demonstrated significant effects of antagonist treatment (P \ 0.0001, F (2,53) = 4152, R 2 = 0.9937). Significant inhibition (44% of that without rapamycin) of S6 K phosphorylation at Effects of cADPR on S6 kinase phosphorylation in the striata of 9-week-old male mice. After adaptive preincubation for 60 min, striatal slices were incubated with or without 100 lM cADPR alone or together with 100 lM 8-bromo-cADPR (8-Br-cADPR) for 5 min at 35°C. Representative Western blots of phosphorylated S6 kinase (Thr389; P-S6 K) and total S6 kinase (S6 K) in the absence (a) or presence (b) of 100 nM DA are illustrated in Fig. 6 of our previous report [9] . Changes in S6 K phosphorylation were quantified after 5-min incubation (P-S6 K/S6 K). Data were calculated as the percentage change between 0 and 5 min (P-S6 K/S6 K at 5 min divided by P-S6 K/S6 K at 0 min). Data are presented as the mean ± SEM of 16 controls (without cADPR and 8-Br-cADPR), 22 preparations treated with cADPR, and eight samples treated with cADPR ? 8-Br-cADPR. One-way ANOVA with Bonferroni's post hoc test was evaluated for significance (see text).
* P \ 0.03 for the comparison of control and 8-Br-cADPR (two-tailed t test) After adaptive preincubation for 60 min, striatal slices were incubated with or without 100 lM cADPR or 100 lM rapamycin for 5 min at 35°C. Changes in S6 K phosphorylation were quantified after 5-min incubation (P-S6 K/S6 K). Data were calculated as the percentage change between 0 and 5 min (P-S6 K/S6 K at 5 min divided by P-S6 K/S6 K at 0 min). Data are presented as the mean ± SEM of 16-22 preparations. P relative to control (two-tailed t test) After adaptive preincubation for 60 min, striatal slices were incubated with or without 100 lM cADPR for 5 min at 35°C. Changes in S6 K phosphorylation were quantified after 5-min incubation (P-S6 K/ S6 K). Data were calculated as the percentage change between 0 and 5 min (P-S6 K/S6 K at 5 min divided by P-S6 K/S6 K at 0 min). Data are presented as the mean ± SEM. N = 14 (none) and N = 16 (?cADPR)
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Thr389 in whole-cell homogenates was obtained with rapamycin (n = 16, P \ 0.001, Bonferroni's post hoc test), which was equivalent to the effect of cADPR (59%) ( Table 2 ). In addition, we determined that the decreased kinase activity is independent of protein kinase C but slightly influenced by protein kinase A (Higashida et al. 2013 ).
Discussion
The results of this study, together with our previous report (Higashida et al. 2013) , indicate that ADP-ribosyl cyclase activity in the mouse striatum is enhanced by DA stimulation during the neonatal period (up to about postnatal day 11) but not in adults. These observations agree with those of our previous study of angiotensin II receptors in ventral cardiac cells (Higashida et al. 2000) , in which activation by angiotensin was observed on neonatal day 4. Similar activation of ADP-ribosyl cyclase by Gs-coupled D1-like receptors and Gi-coupled D2-like receptors was obtained in the mouse striatum. However, this is not unexpected, because we have shown that Gi-coupled mGluR3 (type IIa) stimulates ADP-ribosyl cyclase, while Gs-coupled mGluR1 and mGluR5 (type Ia) also stimulate ADP-ribosyl cyclase . Therefore, DA may play a certain role in the early development through cADPR.
In the adult period, ADP-ribosyl cyclase activity was [40-fold higher in the mouse (current results) and [100-fold higher in the rat (Higashida et al. 2013) . The mRNA and protein levels of CD38 were significantly increased after postnatal days 5-10. It is possible that cADPR is abundant as an endogenous intermediate product of ADPribosyl cyclase and/or CD38 in the adult mouse striatum.
cADPR significantly inhibited the phosphorylation of S6 K, the translational regulatory kinase and downstream target of mTORC1 (Bockaert and Marin 2015; Wullschleger et al. 2006; Hoeffer and Klann 2010) . This cADPR-induced inhibition of S6 K phosphorylation was reproduced by rapamycin, a well-known inhibitor of mTOR signaling through FKBP (Lipton and Sahin 2014; Hoeffer et al. 2008 ). This result seems to indicate that cADPR shares the well-documented rapamycin pathway (Bockaert and Marin 2015; Wullschleger et al. 2006; Lipton and Sahin 2014; Buszczak et al. 2014) . Therefore, since exogenous cADPR and rapamycin inhibited the mTOR pathway, it is possible that endogenously synthesized cADPR functions to inhibit mTOR signaling in the intact adult striatum (Fig. 6) .
Interestingly, with regard to PD, we have shown that cADPR-induced S6 K phosphorylation was diminished in the MPTP-treated mouse brain (see also Higashida et al. 2013 ). This observation is consistent with the enhanced mTOR signaling in the PD model brain (Bockaert and Marin 2015) . It is hypothesized that when the mTOR signal is enhanced by the chronic use of L-DOPA, translation is subsequently increased, which may lead to involuntary movement (Santini et al. 2009; Lipton and Sahin 2014) .
In sum, we propose that the endogenous presence of cADPR is likely a safeguard for maintaining or suppressing translation at a constant rate under conditions of mTOR activation observed in brain dysfunction, such as that in PD (Fig. 6 ).
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